Last reviewed · How we verify
NCT05477940
Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System
NA trial testing Absorbable zinc alloy drug eluting coronary stent system in Coronary Heart Disease in 30 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | Shandong Branden Med.Device Co.,Ltd |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2022 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2024 |
Drugs / interventions tested
- Absorbable zinc alloy drug eluting coronary stent system
Conditions studied
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
- Drug Eluting Stent — all drugs for Drug Eluting Stent →
Sponsor
Shandong Branden Med.Device Co.,Ltd
Who can join
Adults 18 to 75, any sex, with Coronary Heart Disease or Drug Eluting Stent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a prospective, two center single group registration pilot trial aiming to evaluate the product safety, and provide information for the later confirmatory test design according to the results.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05477940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Heart Disease
Currently open trials in the same condition.
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
- NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
- NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting
Other Shandong Branden Med.Device Co.,Ltd trials
Trials by the same sponsor.
- NCT05870449 — The Impact of Climate Environment in Different Latitudes on the Occurrence of PICC Complications · NA · unknown
- NCT05621473 — Comparing the Safety and Effectiveness of Tunnel PICC Guided by EDUG and Conventional PICC · NA · unknown
- NCT05555160 — Application of Intracavity Electrocardiogram Positioning Technique in PICC · NA · unknown
- NCT05676164 — A Study to Evaluate the Safety and Efficacy of Oral Contrast Agent for Sonography · NA · completed
- NCT05651217 — Clinical Study on Disposable Sterile Urinary Catheter · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05477940 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Branden Med.Device Co.,Ltd
- Last refreshed: 28 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05477940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing